Aurobindo Pharma Limited

Aurobindo Pharma Limited announced that its step-down subsidiary, A1 Biochem Labs (India) Private Limited, subscribed to 10,000 equity shares of USD 100 each, totaling USD 1,000,000, in A1 Biochem USA Inc. in the USA on September 11, 2026, as part of the acquisition of the A1 Biochem Group previously disclosed on July 23, 2026.

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1679.8, up 1.19% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.52% on the day, quoting at 23654.75. The Sensex is at 75645.03, down 0.64%. Aurobindo Pharma Ltd has gained around 1.93% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 1.48% in last one month and is currently quoting at 26675.5, up 0.74% on the day. The volume in the stock stood at 7.97 lakh shares today, compared to the daily average of 8.27 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1687.1, up 1.32% on the day. Aurobindo Pharma Ltd is up 60.92% in last one year as compared to a 4.88% slide in NIFTY and a 21.86% slide in the Nifty Pharma index.The PE of the stock is 36.61 based on TTM earnings ending June 26.

Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly-owned subsidiary, Avogent Lifesciences Private Limited, in India on August 31, 2026, with an initial subscribed share capital of Rs 50,00,00,000 divided into 50,00,000 equity shares of Rs 10 each.

Aurobindo Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1700.5, up 3.36% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.42% on the day, quoting at 24073.95. The Sensex is at 76965.47, down 0.39%. Aurobindo Pharma Ltd has risen around 9.38% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 0.81% in last one month and is currently quoting at 26991.85, down 0.42% on the day. The volume in the stock stood at 10.4 lakh shares today, compared to the daily average of 9.96 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1713, up 3.06% on the day. Aurobindo Pharma Ltd is up 65.9% in last one year as compared to a 2.24% drop in NIFTY and a 23.41% drop in the Nifty Pharma index.The PE of the stock is 36.43 based on TTM earnings ending June 26.

Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, Auropharm Overseas Limited, in India with an initial share capital of Rs 10,00,000 divided into 1,00,000 equity shares of Rs 10 each. The object of the newly incorporated subsidiary is to undertake manufacturing and marketing operations in India and foreign countries, and Aurobindo Pharma stated that the acquisition is a related party transaction.

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804) announced its consolidated financial results for the quarter ended June 30, 2026, reporting revenue from operations of INR 9,150 crore, a 16.3% increase year-over-year, driven by growth across its businesses including an 8.1% rise in US revenue to INR 3,770 crore and a 25.6% increase in Europe revenue to INR 2,937 crore. The company’s net profit for the quarter stood at INR 1,032 crore, while its free cash flow reached USD 98 million, and it held a strong net cash position of USD 42 million after investments including the Lannett acquisition and a share buyback. Aurobindo Pharma also received final approval for 10 products from the USFDA.

Aurobindo Pharma Ltd. announced that its board of directors has approved a proposal to merge Eugia Steriles Private Limited and Eugia SEZ Private Limited, both wholly owned step-down subsidiaries, with Eugia Pharma Specialities Limited, a wholly owned subsidiary, through a Scheme of Amalgamation to be filed with the National Company Law Tribunal in Hyderabad. The amalgamation, which is intended to simplify the group structure and create synergy benefits, involves companies engaged in the manufacturing of injectable pharmaceutical products, with Eugia Pharma reporting a turnover of Rs 27,259.04 million for the financial year ended March 31, 2026, Eugia Steriles Rs 62.7 million, and Eugia SEZ Rs 4,874.2 million.

Aurobindo Pharma Ltd share price gained 1.87% to Rs 1613.4 after the company's net profit registered a growth of 12.07% to Rs 1032.03 crore, while revenue from operations slightly gained 4.05% to Rs 9105.82 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, gaining 5.15%. It has marginally improved by 0.66% over last one week and heading higher by 11.72% in last one month while the market capitalization of Aurobindo Pharma Ltd has inched up 1.42% and 9.12% in the same period respectively. Profit before tax (PBT) of Aurobindo Pharma Ltd stood at Rs 1515.09 crore in Q2 FY26, expanding by 25.55% year-on-year, and jumping 17.39% quarter-on-quarter. EBITDA came in at Rs 1617 crore, rising 7.95% YoY and declining 1.16% sequentially. Total expenses posted a minor rise of 2.34% to Rs 7756.11 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 2894.4 crore, going up by 15.53% YoY, while employee benefits expense was at Rs 1480.15 crore, improving by 7.73% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 9.31% to Rs 31378.13 crore, while net profit grew slightly 9.93% to Rs 3483.57 crore, compared to previous TTM. EBITDA surged by 541238% to Rs 5960.94 crore, and PBT expanded by 15.67% to Rs 5066.29 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3924.62 crore in FY26, as against Rs 2434.52 crore in FY25. Aurobindo Pharma Ltd jumped 45.18% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.20% during the same period.

Aurobindo Pharma Limited received a “reasonable assurance” opinion on its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, according to a report released by Sharp & Tannan Associates, Chartered Accountants. The assurance engagement, conducted in accordance with the Standard on Sustainability Assurance Engagements (SSAE) 3000, verified the company’s reported sustainability information against the BRSR Core framework and National Guidelines for Responsible Business Conduct, covering areas such as environmental impact, social responsibility, and governance practices. The Securities and Exchange Board of India (SEBI) mandates BRSR reporting for listed companies in India, and this opinion confirms Aurobindo Pharma’s adherence to the reporting criteria, though the report notes inherent limitations in sustainability reporting and restricts its use to the company’s Board of Directors.

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 5 August 2026.